Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

240 Press Releases
DateTitleCompany
20 May 15 New data show benefit of tiotropium/olodaterol Respimat® from the start of COPD maintenance therapy123 Boehringer Ingelheim,
Published by
Business Wire
18 May 15 Boehringer Ingelheim acquires Pharmaxis’ phase 1 anti-inflammatory drug candidate Boehringer Ingelheim,
Published by
Business Wire
18 May 15 New data and analyses confirm the efficacy and safety of OFEV® (nintedanib*) for the treatment of IPF beyond 52 weeks and for distinct subgroups Boehringer Ingelheim,
Published by
Business Wire
14 May 15 Boehringer Ingelheim showcases expanding presence in lung cancer at ASCO 2015 with new data including presentation of afatinib* overall survival results for squamous cell carcinoma of the lung Boehringer Ingelheim,
Published by
Business Wire
13 May 15 First patient enrolled in dabigatran study comparing anticoagulation strategies during AF ablation Boehringer Ingelheim,
Published by
Business Wire
11 May 15 Boehringer Ingelheim and Sutter Health Establish Research Collaboration to Improve Patient Care Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
17 Apr 15 New international survey of lung cancer oncologists highlights underutilization of personalized treatments Boehringer Ingelheim,
Published by
Business Wire
30 Mar 15 Type 2 diabetes: CHMP recommends empagliflozin/metformin hydrochloride for approval in the European Union Boehringer Ingelheim and Lilly
30 Mar 15 Type 2 Diabetes: CHMP Recommends Empagliflozin/Metformin Hydrochloride for Approval in the European Union Boehringer Ingelheim,
Published by
Business Wire
23 Mar 15 Boehringer Ingelheim’s investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study Boehringer Ingelheim,
Published by
PharmiWeb.com
20 Mar 15 Boehringer Ingelheim’s investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study Boehringer Ingelheim,
Published by
Business Wire
16 Mar 15 Many Atrial Fibrillation patients at high risk of stroke fail to receive guideline-recommended oral anticoagulant treatment Boehringer Ingelheim,
Published by
Business Wire
13 Mar 15 EFSD and Boehringer Ingelheim: celebrating joint research and support Academic Diabetes Research in Europe Boehringer Ingelheim
12 Mar 15 EFSD and Boehringer Ingelheim: celebrating joint research and support Academic Diabetes Research in Europe Boehringer Ingelheim, EFSD,
Published by
PharmiWeb.com
03 Mar 15 Boehringer Ingelheim submits applications for approval of idarucizumab* specific reversal agent to dabigatran etexilate (Pradaxa®) to EMA FDA and Health Canada Boehringer Ingelheim,
Published by
Business Wire
27 Jan 15 New large-scale study to investigate effect of tiotropium + olodaterol Respimat® on exacerbations in COPD Boehringer Ingelheim,
Published by
Business Wire
15 Jan 15 35 Partners from Industry and Academia to Join European Research Initiative for the Prevention of Alzheimer’s Dementia Boehringer Ingelheim,
Published by
Business Wire
12 Jan 15 The Lancet Oncology publishes Phase III data showing Giotrif® (afatinib*) significantly extended overall survival of lung cancer patients with the most common EGFR mutation over chemotherapy Boehringer Ingelheim,
Published by
Business Wire
17 Dec 14 Dabigatran etexilate (Pradaxa®) green-lighted by NICE for treating and preventing the recurrence of deep vein thrombosis and pulmonary embolism. Boehringer Ingelheim Limited,
Published by
Business Wire
19 Nov 14 New data show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans Boehringer Ingelheim,
Published by
Business Wire
16 Oct 14 Boehringer Ingelheim’s OFEV™ (nintedanib*) approved by the FDA for the treatment of idiopathic pulmonary fibrosis Boehringer Ingelheim,
Published by
Business Wire
13 Oct 14 Boehringer Ingelheim Buoyed as Two Medicines Receive Scottish Medicines Consortium (SMC) Green Light for Use within the NHS Boehringer Ingelheim,
Published by
Business Wire
01 Oct 14 Asthma: Spiriva® (tiotropium) Respimat® becomes the only LAMA licensed in asthma care Boehringer Ingelheim
27 Sep 14 Afatinib? demonstrates superior progression-free survival compared to erlotinib in head-to-head Phase III trial in patients with advanced squamous cell carcinoma of the lung after failure of platinum based chemotherapy Boehringer Ingelheim,
Published by
Business Wire
19 Sep 14 Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy Boehringer Ingelheim,
Published by
Business Wire
16 Sep 14 Boehringer Ingelheim Named to Working Mother’s “100 Best Companies for Working Mothers” List Boehringer Ingelheim,
Published by
Business Wire
16 Sep 14 Type 2 Diabetes: Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose in Phase III study Boehringer Ingelheim,
Published by
Business Wire
09 Sep 14 TONADO™ study shows further lung function and quality of life benefits with tiotropium + olodaterol Respimat® fixed dose combination in COPD Boehringer Ingelheim
09 Sep 14 Diabetes: Boehringer Ingelheim and Eli Lilly and Company announce data on portfolio to be presented at the 50th EASD Annual Meeting Boehringer Ingelheim, Eli Lilly,
Published by
PharmiWeb.com
25 Aug 14 New Pradaxa® data to be presented at the ESC Congress 2014 Boehringer Ingelheim,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.